Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) — TITAN

Acquired Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:
A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Status Completed

Clinical Trial Summary

This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP. Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange (PE).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acquired Thrombotic Thrombocytopenic Purpura
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombotic Thrombocytopenic

Clinical Trial Details

NCT number	NCT01151423
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 2
Start date	January 2011
Completion date	March 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02878603` - Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)	Phase 3
Recruiting	`NCT05876221` - Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
Recruiting	`NCT05046717` - Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
Completed	`NCT02553317` - Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura	Phase 3
Recruiting	`NCT04985318` - Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
Not yet recruiting	`NCT04021173` - A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)	Phase 2